Image source: Peppermint.
Peppermint announced $4.7M in seed funding on October 8, 2026. Moxxie led the round. Homebrew, Better Tomorrow Ventures, Layout Ventures, Digital Health Venture Partners, and Night Capital also participated, along with angel investors Benjamin Mann and Evan Moore.
Founders David Freeman and VJ Thurimella previously built payments and reconciliation infrastructure for Robinhood. Peppermint applies that experience to clinical research, offering an AI-powered financial operations platform for teams running trials. The company pairs the software with expert human billers.
The platform pulls data from a site’s clinical trial management software and cross-references it with payment history and trial contracts. It then invoices continuously and pursues collections. The aim is a continuous, audited record of every visit, invoice, and dollar a site is owed, replacing months of manual reconciliation.
With the new funding, Peppermint plans to add budget negotiation, expense management, and clinical trial analytics. The company says it serves clinical research teams and hospital systems across the United States.
Moxxie’s Alex Roetter said there is no standard financial infrastructure for clinical trial billing today. He described Peppermint as bringing the discipline of modern fintech to one of healthcare’s least-examined back offices.
